BCTX · BriaCell Therapeutics Corp
United States · RS rating 20 · As of 2026-11-03
| Price | 3.01 USD |
|---|---|
| 1-day change | -2.6% |
| RS rating (overall / 1M / 3M / 12M) | 20 / 14 / 39 / 11 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 4 / 46 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +40.7% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +76.2% |
| Market cap (USD) | $27.0M |